Next-generation sequencing lung cancer panel identifies more genetic abnormalities

The new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG), now available to support clinical trials through Mayo Clinic Laboratories, uses next-generation sequencing to provide more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.

"This new assay includes almost all genetic and genomic alterations that are currently associated with FDA-approved targeted therapy for lung cancer — in particular, non-small cell lung cancer," says Ying-Chun Lo, M.D., Ph.D. “The panel has a very reasonable turnaround time and relatively low material requirements.”

Mayo Clinic Laboratories has validated MCLNG for use with several different types of surgical and cytological specimens. The test is designed for the assessment of microsatellite instability, which is a biomarker for response to checkpoint inhibitor treatment.

To learn more, check out this test-specific episode of the “Answers From the Lab” podcast on Mayo Clinic Laboratories Insights.

Kevin Ritchart

Kevin Ritchart is a copywriter at Mayo Clinic Laboratories. He joined the company in 2022 and has nearly 10 years of experience writing for healthcare and scientific audiences.